Targeting glycolysis: exploring a new frontier in glioblastoma therapy
- PMID: 39877360
- PMCID: PMC11772265
- DOI: 10.3389/fimmu.2024.1522392
Targeting glycolysis: exploring a new frontier in glioblastoma therapy
Abstract
Glioblastoma(GBM) is a highly malignant primary central nervous system tumor that poses a significant threat to patient survival due to its treatment resistance and rapid recurrence.Current treatment options, including maximal safe surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, have limited efficacy.In recent years, the role of glycolytic metabolic reprogramming in GBM has garnered increasing attention. This review delves into the pivotal role of glycolytic metabolic reprogramming in GBM, with a particular focus on the multifaceted roles of lactate, a key metabolic product, within the tumor microenvironment (TME). Lactate has been implicated in promoting tumor cell proliferation, invasion, and immune evasion. Additionally, this review systematically analyzes potential therapeutic strategies targeting key molecules within the glycolytic pathway, such as Glucose Transporters (GLUTs), Monocarboxylate Transporters(MCTs), Hexokinase 2 (HK2), 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3), Pyruvate Kinase Isozyme Type M2 (PKM2), and the Lactate Dehydrogenase A (LDHA). These studies provide a novel perspective for GBM treatment. Despite progress made in existing research, challenges remain, including drug penetration across the blood-brain barrier, side effects, and resistance. Future research will aim to address these challenges by improving drug delivery, minimizing side effects, and exploring combination therapies with radiotherapy, chemotherapy, and immunotherapy to develop more precise and effective personalized treatment strategies for GBM.
Keywords: glioblastoma; glycolytic metabolic reprogramming; lactate; targeted therapy; tumor microenvironment.
Copyright © 2025 Yang, Li, Yu, Leng and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Silencing BMAL1 promotes M1/M2 polarization through the LDHA/lactate axis to promote GBM sensitivity to bevacizumab.Int Immunopharmacol. 2024 Jun 15;134:112187. doi: 10.1016/j.intimp.2024.112187. Epub 2024 May 10. Int Immunopharmacol. 2024. PMID: 38733825
-
Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [18F]DASA-23.Mol Imaging Biol. 2020 Feb;22(1):124-133. doi: 10.1007/s11307-019-01353-2. Mol Imaging Biol. 2020. PMID: 30989436 Free PMC article.
-
Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy.Biomaterials. 2024 Dec;311:122708. doi: 10.1016/j.biomaterials.2024.122708. Epub 2024 Jul 20. Biomaterials. 2024. PMID: 39047538
-
Recent advances in targeted drug delivery for the treatment of glioblastoma.Nanoscale. 2024 May 9;16(18):8689-8707. doi: 10.1039/d4nr01056f. Nanoscale. 2024. PMID: 38606460 Review.
-
Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment.Biomater Sci. 2024 Aug 6;12(16):4045-4064. doi: 10.1039/d4bm00665h. Biomater Sci. 2024. PMID: 38993162 Review.
Cited by
-
Leveraging adenosine triphosphate for cancer theranostics.Theranostics. 2025 Mar 24;15(10):4708-4733. doi: 10.7150/thno.106291. eCollection 2025. Theranostics. 2025. PMID: 40225571 Free PMC article. Review.
-
Caveolae: Metabolic Platforms at the Crossroads of Health and Disease.Int J Mol Sci. 2025 Mar 24;26(7):2918. doi: 10.3390/ijms26072918. Int J Mol Sci. 2025. PMID: 40243482 Free PMC article. Review.
-
Protein lactylation and immunotherapy in gliomas: A novel regulatory axis in tumor metabolism (Review).Int J Oncol. 2025 Jul;67(1):58. doi: 10.3892/ijo.2025.5764. Epub 2025 Jun 20. Int J Oncol. 2025. PMID: 40539457 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous